EFSA Publishes Criteria for Risk Assessment of Plants Produced by Targeted Mutagenesis, Cisgenesis, and IntragenesisJanuary 25, 2023
The European Food Safety Authority (EFSA) has published the criteria for risk assessment of plants produced by targeted mutagenesis, cisgenesis, and intragenesis. The statement is published in the EFSA Journal.
On April 28, 2022, the European Commission requested EFSA, in accordance with Article 31 of Regulation (EC) No 178/2002, to develop a statement on possible criteria for risk assessment of plants produced by targeted mutagenesis, cisgenesis, and intragenesis. The statement was requested as advice for consideration by the European Commission to support the ongoing policy initiative on plants produced by targeted mutagenesis and cisgenesis. To develop the statement, EFSA considered previously published EFSA Opinions on targeted mutagenesis, cisgenesis, and intragenesis and those assessment aspects discussed by the GMO Panel in the EFSA Opinions on plants developed through synthetic biology which are relevant for the risk assessment of plants developed through targeted mutagenesis, cisgenesis, and intragenesis.
In the Statement, EFSA identified the following criteria:
- Criterion 1: is any exogenous DNA sequence(s) present? This criterion aims to evaluate whether the GM plant contains any exogenous DNA sequence.
- Criterion 2: is the DNA sequence(s) from the breeders' gene pool? In Criterion 2, the GM plant which contains exogenous DNA sequence(s) will be evaluated, which assesses whether the source of the DNA sequence(s) is from the breeders' gene pool.
- Criterion 3: what is the type of integration? Criterion 3 applies only to cisgenic and intragenic plants and defines how the sequence can be introduced.
- Criterion 4: is there an unintended interruption of an endogenous gene? Criterion 4 applies only to cisgenic or intragenic plants for which the type of insertion was random or for SDN-3 approaches for which GSH has not been demonstrated.
- Criterion 5: history of use. The history of use includes the history of safe use (HoSU) for consumers and/or animals and familiarity with the environment which are key elements in the assessment of plants produced by targeted mutagenesis, cisgenesis, and intragenesis.
- Criterion 6: function and structure associated with the new allele. This criterion states that when the HoSU and/or familiarity cannot be sufficiently demonstrated, the risk assessment should focus on the function and the structure associated with the new allele and consider the probability for such an allele to be obtained by conventional breeding.
For more details, download the Statement from the EFSA Journal.
You might also like:
- European Commission Launches Public Consultation on New Genomic Techniques
- EU Commission Seeks Overhaul of GM Law to Address Gene Editing Regulations
- EU Leading Scientists Warn: "European GMO Laws No Longer Fit"
Biotech Updates is a weekly newsletter of ISAAA, a not-for-profit organization. It is distributed for free to over 22,000 subscribers worldwide to inform them about the key developments in biosciences, especially in biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10.
See more articles:
News from Around the World
- Adoption Delay of New Technology Always Disadvantageous to Consumers
- Media and Politics Affect GMO Adoption for Food in Uganda
- UC Riverside Researchers Discover Building Blocks of Photosynthesis
- Asia-Pacific Faces Threat of Urban Food Insecurity
- Building Knowledge and Regulatory Capacity in Animal Biotech in Response to Climate Change
- B-SAFE Webinar Series: Biotechnology Applications and Impact on the Philippine Livestock Industry
- EFSA Publishes Criteria for Risk Assessment of Plants Produced by Targeted Mutagenesis, Cisgenesis, and Intragenesis
- Single Guide RNA for CRISPR-Cas9 System Based on Rice Bacterial Blight Resistance Gene
Read the latest:
- Biotech Updates (December 7, 2023)
- Gene Editing Supplement (November 29, 2023)
- Gene Drive Supplement (February 22, 2023)
Subscribe to BU: